06/19/2020: Lab Advisory: Detection of Ciprofloxacin-resistant, β-lactamase-producing Neisseria meningitidis Serogroup Y Isolates, United States, 2019–2020
Audience: Clinical Laboratory Professionals
Level: Laboratory Advisory
Detection of Ciprofloxacin-resistant, β-lactamase-producing Neisseria meningitidis Serogroup Y Isolates, United States, 2019–2020
Meningococcal disease, which typically presents as meningitis or meningococcemia, is a life-threatening illness that requires prompt antibiotic treatment for patients, and antibiotic prophylaxis for their close contacts. Neisseria meningitidis isolates in the United States have been largely susceptible to the antibiotics recommended for treatment and prophylaxis. However, 11 meningococcal disease cases reported in the United States during 2019–2020 had isolates that contained a blaROB-1 β-lactamase gene associated with penicillin resistance, as well as mutations associated with ciprofloxacin resistance. An additional 22 cases reported during 2013–2020 contained a blaROB-1 β-lactamase gene, but did not have mutations associated with ciprofloxacin resistance.
Laboratories should be aware that CDC recommends that healthcare providers use antimicrobial susceptibility testing (AST) to determine susceptibility of all meningococcal isolates to penicillin before changing from empirical treatment with cefotaxime or ceftriaxone to penicillin or ampicillin.
For more information, read the official CDC Health Advisory.
- CDC’s Laboratory Outreach Communication System (LOCS)
- Register for CDC Health Alert Network (HAN) notifications, including updates about COVID-19. Enter your email address, search for HAN, and sign up